UWM
ORMP icon

Urban Wealth Management’s Oramed Pharmaceuticals ORMP Stock Holding History

Urban Wealth Management’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$13K Buy
+2,858
New +$15.3K 0.04% 185

Other funds holding ORMP

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
JSMC
Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Urban Wealth Management's ORMP Position: Q2 2022 in Review

Urban Wealth Management opened a new position in Oramed Pharmaceuticals (ORMP) in Q2 2022: 2,858 shares worth $13K. The stake represents 0.04% of the portfolio and ranks #185 among its holdings.

88 funds tracked by Wall St. Rank hold ORMP as of Q2 2022.

  • Urban Wealth Management held 2,858 shares of Oramed Pharmaceuticals worth $13K as of Q2 2022.
  • Oramed Pharmaceuticals was a new Urban Wealth Management position in Q2 2022.
  • Oramed Pharmaceuticals made up 0.04% of Urban Wealth Management's portfolio in Q2 2022, its #185 holding.
  • 88 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2022.

Based on Urban Wealth Management's 13F filing for Q2 2022, filed 22 Jul 2022.